Asthma in Children
Conditions
Brief summary
The main purpose of this study is to look at whether clinicians and their patients with asthma can satisfactorily perform remote asthma management at home (not visiting clinic) by using an artificial intelligence tool called Asthma-Guidance and Prediction System combined with a home monitoring device called AsthmaTuner.
Interventions
DEVICEAsthmaTuner
Phone application and spirometer for self-management of asthma
OTHERAsthma-Guidance and Prediction System
Artificial Intelligence (AI)-assisted clinical decision support system which extracts pertinent patient data related to asthma management from electronic health record
Sponsors
Mayo Clinic
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to 17 Years
Healthy volunteers
Yes
Inclusion criteria
Clinician participants are eligible to be included in the study only if all of the following criteria apply: * Employed as consultant or nurse practitioner at study sites. * Able to provide written consent. * Are willing to follow recommendations to schedule/see participant and their caregiver for regular asthma follow-up care every 3-6 months. All asthma care coordinators who are involved in the usual care of pediatric participants will also be recruited for inclusion in the study. Pediatric participants are eligible to be included in the study only if all of the following criteria apply: * Ages 6-17 years old with diagnosis of asthma. * Have a caregiver who is willing to participate alongside pediatric participant and to have regular asthma follow-up care every 3-6 months. * Adolescent participants ages 13-17 years and their caregivers are able to give written informed consent; or child participants ages 7-12 years are able to provide assent and their caregivers are able to give written informed consent (subjects who are 6 years old will be waived). * Both participant and caregiver are able to read and write in English. * Receive pediatric primary care at study sites from participating study clinician. * Access for caregiver and/or adolescent participants to an Android or iPhone with Wi-Fi access and availability for at least monthly use. * Active asthma defined by at least one clinic visit with a diagnosis of asthma per EHR or on active asthma control or rescue medication in the past 12 months. Priority will be given to those with persistent asthma on inhaled corticosteroids therapy or those with poorly controlled asthma defined by any of the following criteria in the past 12 months, except item v (past 2-week period); i. Asthma Control Test for adolescents ≥ 12 years or Childhood Asthma Control Test for children \< 12 years (score\< 20); ii. ED visit for asthma; or iii. Hospitalization for asthma; or iv. Unscheduled outpatient visit for asthma requiring oral corticosteroid use; or v. Asthma symptoms at the screening interview, including 1) more than 2 days per week shortness of breath, wheezing, chest tightness, or 2) more than 1 night awakening due to asthma in the past 2-week period. * Participant had their latest asthma follow-up visit more than 3 months prior to the screening date of the study.
Exclusion criteria
Pediatric participants who do not meet the eligibility criteria described above will be excluded and those will be excluded from the study if any of the following criteria apply: * Major medical problems prohibiting study participation and inability to perform study procedures (including spirometry); suspected symptoms of exercise-induced laryngeal obstruction (EILO), tracheobronchial foreign body at or about the incidence date of asthma, wheezing occurring only in response to anesthesia or medications, bullous emphysema or pulmonary fibrosis on chest radiograph, PiZZ alpha1-antitrypsin, cystic fibrosis, or other major chest disease such as severe kyphoscoliosis or bronchiectasis. * Pediatric participant pregnancy. * Hyposensitization therapy for \> 3 months prior to study enrollment. * Participation in any other interventional studies for asthma within 1 month prior to study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Satisfaction of Asthma Care | Baseline, 6 months | Measured by a single question to assess satisfaction about asthma care using a Likert scale where 1=strongly disagree and 5=strongly agree. Total scores range from 1 to 5, with higher scores indicates greater satisfaction. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Estimated Clinician Preparation Time for Asthma Visits | 6 Months | The number of minutes it took a clinician to review a patient's relevant medical information in preparation for their treatment visit. |
| Change in the Number of Subjects With Poorly Controlled Asthma | Baseline, 6 months | The change in the number of subjects to have poorly controlled asthma defined as Asthma Control Test or Childhood Asthma Control Test score less than 20. |
| Number of On-site Visits | 6 months | Total number of on-site visits participants completed for related asthma care |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORYoung Juhn, MD, MPH
Mayo Clinic
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 11.7 years STANDARD_DEVIATION 2.68 |
| Race/Ethnicity, Customized African American | 0 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 1 Participants |
| Race/Ethnicity, Customized More than one race | 0 Participants |
| Race/Ethnicity, Customized Native Hawaiian/Pacific Islander | 1 Participants |
| Race/Ethnicity, Customized Non-Hispanic White | 8 Participants |
| Race/Ethnicity, Customized Other | 0 Participants |
| Race/Ethnicity, Customized Unknown | 2 Participants |
| Sex/Gender, Customized Female | 28 Participants |
| Sex/Gender, Customized Male | 17 Participants |
| Sex/Gender, Customized Unknown | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 11 | 0 / 11 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 0 / 11 | 0 / 11 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 11 | 0 / 11 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
Outcome results
None listed